Prestige Consumer Healthcare (PBH) Projected to Announce Quarterly Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is anticipated to post its Q1 2027 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $0.8810 per share and revenue of $250.3350 million for the quarter. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Individuals can check the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The firm had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. During the same period last year, the company earned $1.32 EPS. The company’s revenue was down 5.0% compared to the same quarter last year. On average, analysts expect Prestige Consumer Healthcare to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Price Performance

NYSE PBH opened at $51.88 on Wednesday. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. Prestige Consumer Healthcare has a 12-month low of $42.62 and a 12-month high of $75.31. The company has a market capitalization of $2.46 billion, a PE ratio of 13.27, a price-to-earnings-growth ratio of 1.67 and a beta of 0.34. The firm’s 50 day moving average is $48.45 and its 200-day moving average is $56.23.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $70.75.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in PBH. Invesco Ltd. raised its position in Prestige Consumer Healthcare by 7.5% during the fourth quarter. Invesco Ltd. now owns 584,021 shares of the company’s stock worth $36,028,000 after acquiring an additional 40,950 shares in the last quarter. State of Tennessee Department of Treasury increased its stake in shares of Prestige Consumer Healthcare by 2.8% during the 4th quarter. State of Tennessee Department of Treasury now owns 16,049 shares of the company’s stock worth $1,035,000 after purchasing an additional 435 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at about $2,624,000. Millennium Management LLC lifted its stake in Prestige Consumer Healthcare by 72.5% in the 4th quarter. Millennium Management LLC now owns 31,099 shares of the company’s stock valued at $1,918,000 after purchasing an additional 13,069 shares during the last quarter. Finally, Man Group plc grew its holdings in Prestige Consumer Healthcare by 59.3% during the fourth quarter. Man Group plc now owns 173,865 shares of the company’s stock worth $10,726,000 after purchasing an additional 64,755 shares during the period. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).